Neuromod appoints Dr. Jakob Kümmel as Clinical Affairs Manager
DUBLIN, Ireland | Tuesday 19th January 2021: Neuromod Devices Ltd, the Irish medical technology company specialising in non-invasive neuromodulation technologies, has announced the appointment of Dr. Jakob Kümmel as its Clinical Affairs Manager.
In this role, Dr. Kümmel will establish and deliver Neuromod’s clinical training and education programmes for its Lenire® tinnitus treatment system, which was found to improve tinnitus symptoms in 86.2% of treatment-compliant participants after a period of 12 weeks in a recent clinical trial.
Based in Neuromod’s office in Forchheim, Germany, Dr. Kümmel will also manage Neuromod’s partner network across multiple European jurisdictions, helping clinical partners to design treatment plans for different patient types using Lenire.
Dr. Kümmel will also keep partners up to date with the most recent scientific insights and findings from Neuromod’s clinical research programmes and innovations which aim to improve outcomes for patients.
Dr. Kümmel has a wealth of clinical affairs and instructional design experience and comes from Hocoma AG in Swizerland, one of the leading companies in robotic rehab technology and virtual reality in the world, where he was team lead for training, education and clinical affairs.
Before that he was Scientific and Research Advisor at the Human Performance Research Center at Germany’s University Konstanz, where he graduated with a Doctorate, a MSc and Bachelor in Sports Science degrees.
He possesses a strong research background, specialized in the areas of neuromechanics, human movement science and space physiology among other disciplines.
Dr. Kümmel’s appointment comes as Neuromod continues to advance the commercialisation of Lenire across Europe. In October 2020, Neuromod announced it raised €10.5 million in an oversubscribed Series B financing round which is being used to expand European commercialisation and scale-up manufacturing of the Lenire device to meet demand.
Tinnitus affects between 10 and 15% of the global population, and the lives of at least one in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears.
Speaking on this appointment, Dr. Ross O’Neill, CEO of Neuromod said: “I am delighted to announce that Jakob has joined Neuromod as our Clinical Affairs Manager. Jakob’s clinical affairs and instructional design experience will be instrumental in building and developing the relationships we will build with our clinical partners, be they audiologists, GPs or other healthcare professionals, across Europe as we continue to scale up the provision of the Lenire treatment to people currently living with tinnitus.”
Dr Jakob Kümmel said: “I am very excited to take up this role at a company as ambitious and dynamic as Neuromod where I want to build an extensive network of clinical specialists and healthcare professionals to provide clinical and scientific support and design tailored education programmes for customers, patients and distributors to achieve a better understanding of bimodal neuromodulation. This, in turn, will help to improve health outcomes for tinnitus patients all over Europe and beyond.”
For more information please contact:
Senior Communications Manager,
email@example.com / +353 87 670 6826
Notes to Editor:
About Neuromod Devices Limited
Neuromod Devices Limited (“Neuromod”), headquartered in the Digital Hub, Dublin, Ireland, is a medical technology company, specialising in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The company was founded in 2010, by Dr. Ross O’Neill. The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder for which no standard of care has yet been established. Neuromod’s tinnitus treatment device Lenire® has been commercialised in Europe and is available in Ireland, Belgium and Germany. Tinnitus affects between 10 and 15% of the global population, and the lives of at least 1 in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears. For more information visit www.neuromoddevices.com.
Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment shown to soothe and relieve tinnitus in a large-scale clinical trial. Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe. Further details on Lenire including a list of providers can be found at www.lenire.com.
Connect with Neuromod Devices